Trial Profile
Effects of a late add-on therapy of pegylated interferon (peg-IFNA) to ongoing nucleos(t)ide analogs (NUCs) in patients with chronic hepatitis B (CHB).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2015
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Nucleosides; Nucleotides
- Indications Hepatitis B
- Focus Pharmacodynamics
- 01 Sep 2015 New trial record